Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium
This is a Phase IIIb multicentre, randomised, blinded, triple dummy, parallel group study to evaluate the efficacy and safety of UMEC/VI inhalation powder (62.5/25 microgram [mcg] Once daily [QD]) when administered via ELLIPTA®…
- Trial name
- NCT02257385
- Testing
- UMEC/VI, Tiotropium, Indacaterol
- Where
- 84 sites in Argentina, Chile and 10 more
- Volunteers
- 967 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD
The primary objective of the trial is to determine the effect of BI 17444Cl on the lung function over a 24-hour period, when it is inhaled using the Respimat inhaler in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00846768
- Testing
- BI 1744 CL
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe…
- Trial name
- SPRING (NCT01448850)
- Testing
- MEDI8968 600 mg IV, 300 mg SC
- Where
- 60 sites in United States, Bulgaria and 8 more
- Volunteers
- 464 people
- Sponsor
- MedImmune LLC
Pulmonary Disease, Chronic Obstructive
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02233881
- Testing
- Atrovent® - inhalets
- Volunteers
- 4,222 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.
- Trial name
- NCT07108699
- Testing
- HSK39004 Dry Powder Inhaler-0.75mg, HSK39004 Dry Powder Inhaler-1.5mg, HSK39004 Dry Powder Inhaler Simulant
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease (COPD)
A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions
Primary Objective: To evaluate the pharmacokinetics and bioequivalence of the test products Tiotropium Bromide Inhalation Powder (Strength: 18 mcg; manufactured by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) and reference…
- Trial name
- NCT06487416
- Testing
- Tiotropium Bromide Inhalation Powder, Spiriva®Handihaler®
- Where
- China
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)
This study aims to investigate the long-term safety and efficacy of RELVAR® 100 ELLIPTA® (hereinafter referred to as "Relvar") in daily clinical practice in subjects with chronic obstructive pulmonary disease (COPD), who are…
- Trial name
- NCT03219255
- Testing
- RELVAR 100 ELLIPTA
- Where
- 2 sites in Japan
- Volunteers
- 1,047 people
- Sponsor
- GlaxoSmithKline
Respiratory Disorders
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD…
- Trial name
- NCT01360398
- Testing
- Blood sample, Sputum sample, Nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease
A pharmaco-epidemiological, observational study that aimed at assessing in a prospective manner the evolution of Quality of Life (QOL) in chronic obstructive pulmonary disease (COPD) patients treated with inhaled bronchodilators
- Trial name
- NCT02176564
- Testing
- inhaled bronchodilator
- Volunteers
- 2,639 people
- Sponsor
- Boehringer Ingelheim
Chronic Respiratory Failure With Hypercapnia, Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Telemonitoring and Experimentation in Telemedicine for the Improvement of Healthcare Pathways (ETAPES Program) Compared to Standard of Care in Patients With Chronic Respiratory Failure Receiving Non-invasive Home Ventilation
The ETAPES Program, a French national Experimentation in Telemedicine for the Improvement of Healthcare Pathways, was launched in 2018 for 4 years.
- Conditions
- Chronic Respiratory Failure With Hypercapnia, Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS)
- Trial name
- e-VENT (NCT04615078)
- Testing
- ETAPES Program
- Where
- 11 sites in France
- Volunteers
- 56 people
- Sponsor
- Air Liquide Santé International
Pulmonary Disease, Chronic Obstructive
Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment
This study will assess the safety and pharmacokinetics of inhaled GSK573719 and GSK573719/vilanterol combination in healthy subjects and in subjects with severe renal impairment.
- Trial name
- NCT01571999
- Testing
- Inhaled GSK573719, Inhaled GSK573719/vilanterol
- Where
- 2 sites in Czechia, Hungary
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Long-term Safety Study for GSK573719 in Japanese
The objective of this study is to evaluate the safety and tolerability of GSK573719 Inhalation Powder 125 mcg once-daily over 52 weeks in Japanese subjects with COPD.
- Trial name
- AC4115361 (NCT01702363)
- Testing
- GSK573719
- Where
- 20 sites in Japan
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic Treatment
The study will assess the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) stage III and IV who will self administer the AlphaCore stimulation three times a day over a course of 2 months.
- Trial name
- NCT01679314
- Testing
- AlphaCore device
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- ElectroCore INC
Pulmonary Disease, Chronic Obstructive
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
- Trial name
- NCT03979807
- Testing
- Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol
- Where
- United States
- Volunteers
- 11,296 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients
The increased safety and tolerance of single and multiple atomized inhalation of HRS-9821 suspension for inhalation doses in healthy subjects and COPD patients.
- Trial name
- NCT05622864
- Testing
- HRS-9821
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure)
A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults
Prevora is an antiseptic medication and dental treatment approved by Health Canada for reducing root decay (cavities) in adults at high risk of dental decay. An antiseptic kills germs and harmful bacteria.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure), Dialysis, Chronic Metabolic Disorder
- Trial name
- NCT06158633
- Testing
- Prevora
- Volunteers
- 30 people
- Sponsor
- CHX Technologies Inc.
Pulmonary Emphysema
Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205907
- Testing
- BLVR Hydrogel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Aeris Therapeutics
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
This clinical trial aims to assess the impact on exercise tolerance and the safety of inhaled nitric oxide in subjects with moderate-to-severe COPD.
- Trial name
- NCT07382258
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Novlead Inc.
Asthma, COPD
A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
This was an open-label, multiple-dose, study of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 micrograms (mcg) twice daily (BID) (2 puffs of MF/F MDI 50/5 mcg, administered twice a day…
- Trial name
- NCT00604500
- Testing
- SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
- Volunteers
- 272 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.